We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers

By LabMedica International staff writers
Posted on 02 Aug 2018
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.

Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.

The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Clinical Informatics Platform
CLARION™
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Clinical Chemistry

view channel
Image: New recommendations for studying stroke recovery biomarkers could pave the way for more personalized precision rehabilitation (Image Credit: Adobe Stock)

New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation

Stroke affects more than 795,000 Americans each year, leaving many survivors with lasting motor, speech, and cognitive deficits. Because rehabilitation outcomes vary widely, clinicians still face challenges... Read more

Molecular Diagnostics

view channel
Image: A research team led by Prof. Hsing I-Ming (center), Professor of the Department of Chemical and Biological Engineering at HKUST, has developed TEMPO, a thermodynamically programmed one-pot CRISPR platform for rapid, point-of-care nucleic acid testing. Mr. Wu Xiaolong (third right) and Ms. Li Yanan (first left), PhD students from the Department of Chemical and Biological Engineering, are the co-first authors of this study. (Photo courtesy of HKUST)

Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes

Rapid, accurate detection of infectious agents and single-nucleotide variants remains difficult to deliver outside centralized laboratories. Although multi-step nucleic acid workflows are sensitive, they... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Journal Addresses Evolving Needs in Clinical and Translational Pathology

Clinical pathology underpins diagnosis and therapy selection across oncology and other major diseases, but the field is rapidly evolving as new technologies reshape how disease is studied and classified.... Read more